A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma

Trial Profile

A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Clarithromycin; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms CarBiRD
  • Most Recent Events

    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Status changed from recruiting to completed,according to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 22 May 2013 Results will be presented at the 18th Congress of the European Hematology Association (EHA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top